

From: [Bryan McCarthy](#)
To: [SLegislation](#)
Cc: [Sen. Murray, Melissa A.](#); [Sen. Lauria, Pamela J.](#); [Sen. Urso, Lori](#); [Sen. Appollonio, Peter A. Jr.](#); [Sen. Rogers, Gordon E.](#); [Sen. Thompson, Brian J.](#); [Sen. Ujifusa, Linda L.](#); [Sen. Valverde, Bridget G.](#); [Sen. Lawson, Valarie J.](#); [Sen. Ciccone III, Frank A.](#); Sen-tikpoian@rilegislature.gov; [Kristen Silvia](mailto:Kristen.Silvia); info@ripharmacists.org; Cfedericorx@gmail.com
Subject: Support S2112 - Glucagon Access for Diabetes
Date: Tuesday, April 14, 2026 1:49:52 PM

You don't often get email from bryanmccarthy@gmail.com. [Learn why this is important](#)

Bryan McCarthy, PharmD

Vice President & Chief Pharmacy Officer
Providence, Rhode Island

The Honorable Members of the Senate Health & Human Services Committee

Rhode Island General Assembly
State House
Providence, RI

Re: Support for S2112 – Coverage for Glucagon Hypoglycemia Medications

Dear Chair and Honorable Members of the Committee,

I am writing in my **personal professional capacity as a licensed pharmacist and health system pharmacy leader in Rhode Island** to express my strong support for **Senate Bill S2112**. The views expressed here are my own and are not intended to represent an official position of my employer or any affiliated organization.

In my clinical and administrative experience, I have seen firsthand the serious and sometimes life-threatening consequences of severe hypoglycemia. Glucagon is a **life-saving medication** that must be administered rapidly to be effective, often by caregivers, family members, school staff, or other non-clinicians in emergency situations. Traditional glucagon products that require reconstitution present real barriers during emergencies, while newer ready-to-use formulations are frequently underutilized due to cost-sharing and access limitations.

S2112 appropriately recognizes that severe hypoglycemia is a significant barrier to effective diabetes management and is associated with increased emergency department utilization, hospital admissions, patient anxiety, and overall cost of care. Ensuring coverage for modern glucagon formulations without copayments or deductibles would meaningfully improve patient safety, emergency preparedness, and health outcomes for individuals living with diabetes across Rhode Island.

From both a clinical and health-system perspective, improving access to user-friendly glucagon products supports safer outpatient management, reduces preventable acute care utilization, and aligns with broader public health goals focused on harm reduction and patient empowerment.

For these reasons, I strongly support the passage of S2112 and respectfully urge the Committee to advance this legislation. Thank you for your consideration and for your continued commitment to

improving the health and safety of Rhode Islanders.

Sincerely,

Bryan McCarthy, PharmD

Licensed Pharmacist, Rhode Island

--

Bryan C. McCarthy Jr., Pharm.D., M.S., M.J